Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: Studies in atherosclerotic mice and in humans

Drugs under Experimental and Clinical Research

Volumn 28, Issue 2-3, 2002, Pages 49-62

  Aviram, M ^a   Dornfeld, L ^a   Kaplan, M ^a   Coleman, R ^a   Gaitini, D ^a   Nitecki, S ^a   Hofman, A ^a   Rosenblat, M ^a   Volkova, N ^a   Presser, D ^a   Attias, J ^a   Hayek, T ^a   Fuhrman, B ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHOCYANIDIN; ANTHOCYANIN; APOLIPOPROTEIN E; CYTOCHROME P450; DAIDZEIN; DIPEPTIDYL CARBOXYPEPTIDASE; ESTROGEN; ESTRONE; FLAVONOID; GENISTEIN; LOW DENSITY LIPOPROTEIN; PHYTOESTROGEN; PLANT EXTRACT; POLYPHENOL; POMEGRANATE EXTRACT; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DRUG MECHANISM; ENZYME ACTIVITY; FRUIT JUICE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; POMEGRANATE; STRUCTURE ACTIVITY RELATION; TIME SERIES ANALYSIS; TRADITIONAL MEDICINE; VEGETABLE;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; FLAVONOIDS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MICE; OXIDATION-REDUCTION; PUNICACEAE;

EID: 0036933448     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Schaffner T., Taylor K., Bartucci E.J., et al. Arterial foam cells with distinctive immuno-morphologic and histochemical features of macrophages. Am. J. Pathol., 100, 57, 1980.
2. Gerrity R.G. The role of monocytes in atherogenesis. Am. J. Pathol., 103, 181, 1981.
3. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature, 343, 425, 1990.
4. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science, 232, 34, 1986.
5. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J Med., 320, 915, 1989.
6. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis, 98, 1, 1993.
7. Aviram M. Beyond cholesterol: Modifications of lipoproteins and increased atherogenicity. In: Neri Serneri G.G., Gensini G.F., Abbate R., Prisco D. (Eds.) "Atherosclerosis Inflammation and Thrombosis." Scientific Press, Florence, 1993, pp. 15-36.
8. Aviram M., Rosenblat M. Oxidative stress in cardiovascular diseases: Role of oxidized lipoproteins in macrophage foam cell formation and atherosclerosis. In: Fuchs J., Podda M., Packer L. (Eds.) "Redox Genome Interactions in Health and Disease." Marcel Dekker, New York, 2002, in press.
9. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular disease. Free Radic. Res., 33, S85, 2000.
10. Aviram M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and antioxidants in arterial cells and blood lipoproteins. Antiox. Redox. Signal., 1, 585, 1999.
11. Ross R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med., 340, 115, 1999.
12. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol., 15, 551, 1995.
13. Williams K.J., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol., 9, 471, 1998.
14. Nordestgaard B.G. The vascular endothelial barrier-selective retention of lipoproteins. Curr. Opin. Lipidol., 7, 269, 1996.
15. Schwenke D.C., Carew T.E. Initiation of atherosclerotic lesions in cholesterol-fed rabbits I: Focal increases in arterial LDL concentrations precede development of fatty streak lesions. Arteriosclerosis, 9, 895, 1989.
16. Schwenke D.C., Carew T.E. Initiation of atherosclerotic lesions in cholesterol-fed rabbits II: Selective retention of LDL vs. selective increase in LDL permeability in susceptible sites of arteries. Arteriosclerosis, 9, 908, 1989.
17. Carmena R., Ascaso J.F., Camejo G., et al. Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation, and interaction with arterial proteoglycans. Atherosclerosis, 125, 243, 1996.
18. Camejo G., Hurt-Camejo E., Olson U., Bonders G. Proteoglycans and lipoproteins in atherosclerosis. Curr. Opin. Lipidol., 4, 385, 1993.
19. Ismail N.A., Alavi M.Z., Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis, 105, 79, 1994.
20. Kostner G.M., Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J., 11 (Suppl. E), 184, 1990.
21. Vijayagopal P., Srinivasan S.R., Radhakrishnamurthy B., Berenson G.S. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocyte/macrophages. Arterioscler. Thromb., 12, 237, 1992.
22. Hurt E., Bonders G., Camejo G. Interaction of LDL with human arterial proteoglycans stimulates its uptake by human monocyte-derived macrophages. J. Lipid Res., 31, 443, 1990.
23. Aviram M., Maor I., Keidar S., et al. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem. Biophys. Res. Commun., 216, 501, 1995.
24. Pentikainen M.O., Lethonen E.M., Kovanen P.T. Aggregation and fusion of modified low density lipoprotein. J. Lipid Res., 37, 2638, 1996.
25. Schissel S.L., Tweedie-Hardman J., Rapp J.H., Graham G., Williams K.J., Tabas I. Rabbit aorta and human atherosclerotic lesion hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest., 98, 1455, 1996.
26. Zhang W.Y., Gaynor P.M., Kruth H.S. Aggregated low density lipoprotein induces and enters surface-connected compartments of human monocyte-macrophages. Uptake occurs independently of the low density lipoprotein receptor. J. Biol. Chem., 272, 31700, 1997.
27. Hoff H.F., O'Neil Y. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler. Thromb. Vasc. Biol., 11, 1209, 1991.
28. Hoff H.F., Whitaker T.E., O'Neil Y. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J. Biol. Chem., 267, 602, 1992.
29. Maor I., Hayek T., Coleman R., Aviram M. Plasma LDL oxidation leads to its aggregation in atherosclerotic apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 17, 2995, 1997.
30. Hurt-Camejo E., Camejo G., Rosengren B., et al. Effect of arterial proteoglycan and g/ycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler. Thromb., 12, 569, 1992.
31. Jialal I., Devaraj S. The role of oxidized low density lipoprotein in atherogenesis. J. Nutr., 126, 1053, 1996.
32. Steinberg D. Low density-lipoprotein oxidation and its pathobiological significance. J. Biol. Chem., 272, 20963, 1997.
33. Berliner J.A., Heinecke J.W. The role of oxidized/lipoproteins in atherosclerosis. Free Radic. Biol. Med., 20, 707, 1996.
34. Aviram M. Oxidative modification of low density lipoprotein and atherosclerosis. Isr. J. Med. Sci., 31, 241, 1995.
35. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 88, 1785, 1991.
36. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem., 34, 599, 1996.
37. Kaplan M., Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin. Chem. Lab. Med., 37, 777, 1999.
38. Parthasarathy S., Santanam N., Auge N. Oxidized low-density lipoprotein, a two-faced janus in coronary artery disease? Biochem. Pharmacol., 56, 279, 1998.
39. Parthasarathy S., Rankin S.M. The role of oxidized LDL in atherogenesis. Prog. Lipid Res., 31, 127, 1992.
40. Aviram M. Antioxidants in restenosis and atherosclerosis. Curr. Interven. Cardiol. Rep., 1, 66, 1999.
41. Herttuala S.Y. Is oxidized low density lipoprotein present in vivo? Curr. Opin. Lipidol., 9, 337, 1998.
42. Aviram M. The contribution of the macrophage receptor for oxidized LDL to its cellular uptake. Biochem. Biophys. Res. Commun., 179, 359, 1991.
43. Kim J.A., Territo M.C., Wayner E., et al. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler. Thromb., 14, 427, 1994.
44. Khan N.B.V., Parthasarathy S., Alexander R.W. Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest., 95, 1262, 1995.
45. Rangaswamy S., Penn M.S., Saidel G.M., Chisolm G.M. Exogenous oxidized low density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ. Res., 80, 37, 1997.
46. Penn M.S., Chisolm G.M. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis, 108, 21, 1994.
47. Brown A.J., Leong S.L., Dean R.T., Jessup W. 7-Hydroxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J. Lipid Res., 38, 1730, 1997.
48. Lynch S.M., Morrow J.D., Roberts II L.J., Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest., 93, 998, 1994.
49. Slatter D.A., Paul R.G., Murray M., Bailey A.J. Reactions of lipid derived malondialdehyde with collagen. J. Biol. Chem., 274, 19661, 1999.
50. Jessup W., Mander E.L., Dean R.T. The intracellular storage and turnover of apolipoprotein B of oxidized LDL in macrophages. Biochim. Biophys. Acta., 1126, 167, 1992.
51. Chisolm G.M., Hazen S.T., Fox P.L., Catchard M.K. The oxidation of lipoproteins by monocyte-macrophages. J. Biol. Chem., 274, 25959, 1999.
52. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis, 6, 505, 1986.
53. Aviram M., Fuhrman B. LDL oxidation by arterial wall macrophages depends on the antioxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants. Mol. Cell Biochem., 188, 149, 1998.
54. Aviram M., Rosenblat M. Macrophage mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J. Lipid Res., 35, 385, 1994.
55. Aviram M., Rosenblat M., Etzioni A., Levy R. Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein. Metabolism, 45, 1069, 1996.
56. Herttuala Y.S., Rosenfeld M.E., Parthasarathy S., et al. Colocallzation of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA, 87, 6959, 1990.
57. Aviram M., Kent U.M., Hollenberg P.F. Microsomal cytochrom P450 catalyze the oxidation of low density lipoprotein. Atherosclerosis, 143, 253, 1999.
58. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem., 52, 711, 1983.
59. Rosenblat M., Aviram M. Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL. Free Radic. Biol. Med., 24, 305, 1997.
60. Fuhrman B., Oiknine J., Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affect their secretory properties. Atherosclerosis, 111, 65, 1994.
61. Fuhrman B., Oiknine J., Keidar S., Kaplan M., Aviram M. increased uptake of low density lipoprotein (LDL) by oxidized macrophages is the result of enhanced LDL receptor activity and of progressive LDL oxidation. Free Radic. Biol. Med., 23, 34, 1997.
62. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonases biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol., 7, 69, 1996.
63. La Du B.N., Adkins S., Kuo C.L., Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact., 87, 25, 1993.
64. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med., 5, 381, 1999.
65. Aviram M. Paraoxonase protects lipoproteins from oxidation and attenuates atherosclerosis. Ateroscleroza, 4, 3, 2000.
66. La Du B.N., Aviram M., Billecke S., et al. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact., 119, 379, 1999.
67. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 86, 193, 1991.
68. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol., 15, 1812, 1995.
69. Garin M.C., James R.W. Dussoix P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest., 99, 62, 1997.
70. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest., 101, 1581, 1998.
71. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol., 8, 1617, 1998.
72. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med., 26, 892, 1999.
73. Fuhrman B., Aviram M. Anti-atherogenicity of nutritional antioxidants. Drugs, 4, 82, 2001.
74. Hertog M.G., Kromhout D., Aravanis C., et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med., 155, 381, 1995.
75. Aviram M., Fuhrman B. Effects of flavonoids on the oxidation of LDL and atherosclerosis. In: Rice-Evans C., Packer L. (Eds.). "Flavonoids in health and disease." Second Edition, Marcel Dekker, New York, 2002, in press.
76. Rice-Evans C.A., Miller N.J., Bolwell P.G., Bramley P.M., Pridham J.B. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res., 22, 375, 1995.
77. Rice-Evans C.A., Miller N.J., Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med., 20, 933, 1996.
78. Van Acker S.A.B.E., Van-den Berg D.J., Tromp M.N.J.L., et al. Structural aspects of antioxidants activity of flavonoids. Free Radic. Biol. Med., 20, 331, 1996.
79. Rosenblat M., Belinky P., Vaya J., et al. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell mediated oxidation of low density lipoprotein. J. Biol. Chem., 274, 13790, 1999.
80. Langley P. Why a pomegranate? Br. Med. J., 321, 1153, 2000.
81. Aviram M. Polyphenols from pomegranate juice, red wine and licorice root protect agafnst lipids peroxidation and attenuate cardiovascular diseases. In: "Polyphenols 2000." Proc. XX Int. Conf. Polyphenols. Martens S., Treutter D., Forkmann G. (Eds.). Freising-Weihenstephan, Freising, 2002, pp. 158-175.
82. Ben Nasr C., Ayed N., Metche M. Ouantitative determination of the polyphenolic content of pomegranate peel. Z. Lebensm. Unters. Forsch., 203, 374, 1996.
83. El-Toumy S.A., Marzouk M.S. Rauwald H.W. Ellagic- and gallotannfns from Punica granatum heartwood. Pharmazie, 10, 823, 2001.
84. Gil M.I., Tomas-Barberan F.A., Hess-Pierce B., Holcroft D.M., Kader A.A. Antioxidant activity of pomegranate julbe and its relationship with phenolic composition and processing. J. Agric. Food Chem., 48, 4581, 2000.
85. Heftaman E., Bennett S.T. Identification of estrone in pomegranate seeds. Phytochemistry, 5, 1337, 1966.
86. Moneam N.M.A., El Sharasky A.S., Badreldin M.M. Oestrogen content of pomegranate seeds. J. Chromatogr., 438, 438, 1988.
87. Sharaf A., Nigm S.A.R. The oestrogenic acitvity of pomegranate seed oil. J. Endocrinol., 29, 91, 1964.
88. Shubert Y.S., Lansky E.P., Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. Ethnopharmacol., 66, 11, 1999.
89. Aviram M., Dorenfeld L., Rosenblat M., et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: Studies in humans and in the atherosclerotic apolipoprotein E deficient mice. Am. J. Clin. Nutr., 71, 1062, 2000.
90. Aviram M., Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis, 158, 195, 2001.
91. He K., Lyer K.R., Hayes R.N., et al. Inactivation of cytochrome P-450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol., 11, 252, 1998.
92. Kaplan M., Hayek T., Raz A., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophages lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr., 131, 2082, 2001.
93. Aviram M., Fuhrman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis, 137 (Suppl.), S45, 1998.
94. Fuhrman B., Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr. Opin. Lipidol., 12, 41, 2001.
95. Fuhrman B., Aviram M. Polyphenols and flavonoids protect LDL against atherogenic modifications. In: Cadenas E., Packer L. (Eds.). "Handbook of Antioxidants: Biochemical, Nutritional and Clinical Aspects." Second Edition. Marcel Dekker, New York, 2001, pp. 303-336.
96. Vaya J., Aviram M. Nutritional antioxidants: Mechanisms of action, analyses of activities and medical application. Curr. Med. Chem. Imm. Endoc. Metab. Agents, 1, 99, 2001.